Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023)
Ani Pharmaceuticals' (ANIP) quarterly Restructuring Costs came in at $2000.0 in Q2 2023, down 99.92% year-over-year from $2.6 million in Q2 2022, and down 99.82% quarter-over-quarter from $1.1 million in Q1 2023.
Powered by 
Analysis
Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023) Analysis & Trends
Ani Pharmaceuticals has disclosed Restructuring Costs across 2 years of filings, most recently posting $2000.0 for Q2 2023.
- In Q2 2023, Restructuring Costs fell 99.92% year-over-year to $2000.0; the TTM figure through Mar 2024 stood at $2000.0 (down 99.97% YoY), while the FY2023 annual figure was $1.1 million, down 80.07% from the prior year.
- Restructuring Costs came in at $2000.0 for Q2 2023 at Ani Pharmaceuticals, down from $1.1 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $2.6 million in Q2 2022 to a low of $2000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Jun 30, 2022 | 2.57 Mn |